3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A CH2, C-H technology, applied in the field of compounds for the treatment of these pathological conditions, and the field of synaptic receptors, can solve the problems of uncertain mechanism of effect and low activity
Inactive Publication Date: 2010-08-11
CORTEX PHARMA
View PDF8 Cites 1 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
The metabolite anisoyl-GABA has been found to be less active than aniracetam
In addition to these, aniracetam is speculated to affect numerous other neurotransmitter and enzyme sites in the brain, making the mechanism of any purported therapeutic drug effect uncertain
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
[0449] Intermediates 7 and 8 (2.70 g, 9.8 mmol) were dissolved in THF (100 ml) and methanol (75 ml). A solution of potassium hydroxide (6.0 g) in water (60 ml) was added and the mixture was stirred (20°C) for 45 minutes. Hydrochloric acid was added to the mixture (to pH 2) and the solvent was evaporated. The mixture was dissolved in DMF (100ml) and the solvent was evaporated to remove water. (2R)-1-(2H-tetrazol-2-yl)propan-2-amine hydrochloride (2.0 g, 10 mmol) and DMF (100 ml) were added and the solvent was evaporated. Add DMF (80ml), dimethylaminopiperidine (DMAP) (1.22g, 10mmol), hydroxybenzotriazole (HOBT) (1.35g, 10mmol), NEt 3 (2ml) and N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide (EDCI) (5.5g, 28.5mmol) and the mixture was stirred at 45°C under nitrogen for 4 hours. Evaporate the solvent, add water (100ml), use 2N H 2...
[0453] The title compound was prepared from Intermediate 3 following the procedure of Example 1. The obtained white solid has the following characteristics: mp=157-160°C; 1 H NMR (300MHz, CDCl 3 )δ9.15(1H, s), 9.05(1H, s), 5.90-5.75(1H, m), 5.26(1H, dd, J=8.4 and 14.4Hz), 5.05(1H, dd, J=4.8 and 14.4 Hz), 4.12-4.02 (1H, m), 2.44 (3H, s), 1.79 (3H, d, J = 6.9 Hz) and 1.48-1.24 ppm (4H, m).
[0457] Intermediate 4 was used to prepare the title compound following the procedure of Example 1. The obtained white solid has the following characteristics: mp=208-211°C; 1 H NMR (300MHz, CDCl 3 )δ9.14(1H, s), 9.02(1H, s), 5.90-5.79(1H, m), 5.03(1H, dd, J=9.6 and 14.4Hz), 4.69(1H, dd, J=5.1 and 14.4Hz), 4.11-4.03 (1H, m), 2.62 (3H, s), 1.80 (3H, d, J = 6.9Hz) and 1.45-1.25ppm (4H, m).
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in regulation of breathing, and cognitive abilities related to memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia, respiratory depression, sleep apneas, attention deficit hyperactivity disorder and affective or mood disorders, and in disorders wherein a deficiency in neurotrophic factors is implicated, as well as in disorders of respiration such as overdose of an alcohol, an opiate, an opioid, a barbiturate, an anesthetic, or a nerve toxin, or where the respiratory depression results form a medical condition such as central sleep apnea, stroke- induced central sleep apnea, obstructive sleep apnea, congenital hypoventilation syndrome, obesity hypoventilation syndrome, sudden infant death syndrome, Rett syndrome, spinal cord injury, traumatic brain injury, Cheney-Stokes respiration, Ondines curse, Prader-Willi's syndrome and drowning. In a particular aspect, the invention relates to compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.
Description
technical field [0001] The present invention relates to compounds, pharmaceutical compositions and methods for the prevention and treatment of cerebral insufficiency, including the enhancement of receptors acting on synapses in brain networks responsible for various behaviors. These brain networks are involved in basic functions such as breathing, to more complex functions such as memory and cognition. Imbalances in neural activity between different brain regions can lead to many diseases, including psychiatric and neurological disorders, including memory deficits, Parkinson's disease, schizophrenia, attention deficits and affective or mood disorders, respiratory depression and neurological deficits involving Diseases of nutritional factors. In particular, the invention relates to compounds useful in the treatment of these conditions, and methods of treatment using such compounds. [0002] related application [0003] This application claims priority to US Provisional Appli...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more